5 results about "Protein subunit" patented technology

The application relates to preparation and application of a giant Eimeria nanosubunit vaccine. The nanosubunit vaccine PLGA-rEmLPL is prepared by coating E. maxima Treg-induced molecule EmLPL recombinant protein (rEmLPL) with PLGA nanoparticles. The immunoprotective effects of the subunit vaccine rEmLPL and the nanosubunit vaccine PLGA-rEmLPL are evaluated through animal immunoprotection tests, and the results show that both the vaccines can produce good immunoprotective effects on E. maxima infection. After the recombinant protein subunit vaccine rEmLPL is coated with the PLGA nanoparticles, the immunoprotective effect of the nanosubunit vaccine PLGA-rEmLPL on animals is improved compared with that of the subunit vaccine rEmLPL.

This invention relates to the field of pharmaceutical technology, and more particularly to fusion proteins of human heavy chain ferritin or its variants with polyhedral or granular proteins and their applications. This invention fuses a ferritin variant with a baculovirus polyhedral protein subunit to obtain particles with a diameter <20 nm, consisting of a polyhedral protein outer layer and a ferritin inner layer. The particles have an outer diameter of 17 nm, an inner lumen of 13 nm, and are positively charged. pH adjustment enables the depolymerization and recombination of the outer and inner layers, allowing the encapsulation of negatively charged insulin molecules with a diameter >8 nm. Proteins fused with polyhedral or granular protein subunits to wild-type or mutant ferritin can self-assemble into bilayer nanoparticles. The inner layer is a cage-like structure with a positive or negatively charged lumen and a size of 8 nm or 13 nm; the outer layer is a polyhedral or granular protein layer, exhibiting resilience, resistant to high temperatures and dehydration, and resistant to digestion by pepsin and trypsin. These nanoparticles can serve as oral carriers for various active molecules.

The application relates to preparation and application of a nano-subunit vaccine for preventing chicken coccidiosis. The nano-subunit vaccine PLGA-rEmTregIM-1 is prepared by coating a giant Eimeria maxima Treg inducing molecule EmTregIM-1 recombinant protein (rEmTregIM-1) with PLGA nanoparticles. The immunoprotective effects of the subunit vaccine rEmTregIM-1 and the nano-subunit vaccine PLGA-rEmTregIM-1 are evaluated through animal immunoprotection tests, and the results show that both the vaccines can produce partial immunoprotections for the giant Eimeria maxima infection. After the recombinant protein subunit vaccine rEmTregIM-1 is coated with the PLGA nanoparticles, the nano-subunit vaccine PLGA-rEmTregIM-1 has an improved immunoprotection effect on animals compared with the subunit vaccine rEmTregIM-1.

The present disclosure relates to fusion proteins comprising a mutant IL-2 polypeptide subunit and one or two antigen binding domains (e.g., VHH antibodies) that specifically bind to an antigen expressed on the surface of immune cells such as tumor reactive T cells expressing CD8 and / or PD1. The fusion can also comprise a half-life extending protein subunit such as an Ig1 Fc region monomer polypeptide. The present disclosure also relates to the use of these fusion proteins as therapeutic agents, for example, in pharmaceutical compositions for treating cancer and autoimmune disorders.

This invention belongs to the field of biotechnology, specifically relating to a method and application for the isolation and preparation of detached spike protein S1 subunits. This invention successfully isolates detached S1 protein subunits using PEG precipitation, a rapid, convenient, and reliable method that yields structurally correct and stable S1 units. By simulating the binding of the spike protein to ACE2 during coronavirus infection, the S1 subunit is detached. The tag carried by the S1 subunit is then used to isolate and purify the naturally detached S1 subunit, resulting in structurally correct and stable S1 units. The S1 subunit protein is a core functional unit for viral invasion; drug design based on its naturally detached structure can efficiently inhibit viral fusion and is an important target for screening blocking agents (such as small molecules, antibodies, and nucleic acid aptamers). The detached S1 subunit retains an intact antigenic epitope and can be used as a core reagent in detection methods such as ELISA, immunochromatography, and biosensors for detecting viruses or neutralizing antibodies.